2021
DOI: 10.1101/2021.06.09.447779
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Genetic analysis of praziquantel response in schistosome parasites implicates a Transient Receptor Potential channel

Abstract: Mass treatment with praziquantel (PZQ) monotherapy is the mainstay for schistosome treatment. This drug shows imperfect cure rates in the field and parasites showing reduced response to PZQ can be selected in the laboratory, but the extent of resistance in Schistosoma mansoni populations is unknown. We examined the genetic basis of variation in PZQ response in a S. mansoni population (SmLE-PZQ-R) selected with PZQ in the laboratory: 35% of these worms survive high dose (73 ug/mL) PZQ treatment. We used genome … Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
3
1
1

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(1 citation statement)
references
References 80 publications
(46 reference statements)
0
1
0
Order By: Relevance
“…A recent metaanalysis of PZQ efficacy over four decades indicates cure rates between 57-88% (2), but there is the concern that resistance may emerge with repeated rounds of mass drug administration (3). Parasite resistance can be selected in the laboratory (4)(5)(6), and there are numerous reports of treatment failure in the field (7,8). An alternative antischistosomal drug would be of obvious use in the event of either PZQ treatment failure or resistance.…”
Section: Introductionmentioning
confidence: 99%
“…A recent metaanalysis of PZQ efficacy over four decades indicates cure rates between 57-88% (2), but there is the concern that resistance may emerge with repeated rounds of mass drug administration (3). Parasite resistance can be selected in the laboratory (4)(5)(6), and there are numerous reports of treatment failure in the field (7,8). An alternative antischistosomal drug would be of obvious use in the event of either PZQ treatment failure or resistance.…”
Section: Introductionmentioning
confidence: 99%